Insulin: $35 Monthly Cost Cap
The Insulin Act of 2026 was recently introduced in the Senate and sent to the Committee on Health, Education, Labor, and Pensions for review. It is currently in the early stages of the legislative process and is waiting for committee action. There are no upcoming votes scheduled at this time.
This bill has very strong bipartisan support in the Senate and addresses a high priority issue for voters in both parties.
This bill’s path across every version that has carried it.
Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
Employers who sponsor group health plans must cover selected insulin at the capped cost and cannot require prior authorization on those products. Full rebate pass-through rules could lower plan drug spending, but plans also lose the ability to charge higher insulin cost-sharing, which may shift some costs.
“shall remit 100 percent of rebates, fees, alternative discounts, and all other remuneration received from a pharmaceutical manufacturer, distributor or any other third party, that are related to utilization of insulin under such health plan or health insurance coverage, to the group health plan.”
Placed on Senate Legislative Calendar under General Orders. Calendar No. 552.
The bill is now on the schedule for the full chamber to consider. It's in line for debate and a vote.
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
The committee approved this bill and is sending it to the full chamber for a vote. This is a significant step — most bills never get this far.
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
The committee approved this bill and is sending it to the full chamber for a vote. This is a significant step — most bills never get this far.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
A bipartisan group of senators introduced the INSULIN Act to cap the cost of the lifesaving drug at $35 per month for Americans with private insurance. The bill also includes a pilot program for uninsured patients in 10 states, building on previous Medicare caps.
The INSULIN Act of 2026 proposes a $35 monthly cap for commercial insurance and a 5-year pilot program for the uninsured. Experts note the bill requires plans to waive deductibles for at least one insulin of each type, though some worry about the granularity of coverage for specific products.
Lawmakers reached a breakthrough on the INSULIN Act, a bipartisan effort to extend the $35 monthly price cap to the private market. The bill aims to address root causes of high list prices by fostering competition and curbing patent abuses that delay lower-cost generic alternatives.
No votes recorded for this bill yet.
Document Type
Congressional Bill
Official Title
INSULIN Act of 2026
Analysis generated by AI. Always verify with official sources.